# Administration of ARS-1 or Albuterol in Subjects With Persistent Asthma

> **NCT05363670** · PHASE2 · COMPLETED · sponsor: **ARS Pharmaceuticals, Inc.** · enrollment: 18 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** ARS-1
- **DRUG:** Albuterol MDI
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05363670
- **Lead sponsor:** ARS Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-28
- **Primary completion:** 2024-02-02
- **Final completion:** 2024-02-02
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2024-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05363670

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05363670, "Administration of ARS-1 or Albuterol in Subjects With Persistent Asthma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05363670. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*